Eurofins Medigenomix and MWG Biotech AG will analyse the genetic differences between Wacker's proprietary industrial protein production E.coli strain and its corresponding parental strain.
This is the result of a genome-sequencing project between the three companies.
The successful sequencing is an important step to further improve and advance Wacker's E.coli strain and the related proprietary E.coli secretion system, which makes proteins in a cost-efficient manner.
The genome of the E.coli strain was sequenced with ultra parallel shotgun sequencing using GS 20 technology, a high-throughput automated DNA sequencing system.
The sequence reads have been assembled into contigs - sets of overlapping DNA segments - and subsequently analysed with MWG's proprietary genome-comparison tool and displayed with the MWG's Annotation Viewer software.
Wacker's E.coli secretion system is a commercialised and well-established technology for protein production.
The core of the technology is Wacker's E.coli K12 strain, which can secrete a variety of different recombinant proteins in their native form into the fermentation broth during cultivation.
Extracellular production facilitates straightforward purification of recombinant products, eliminates tedious refolding steps and makes the whole manufacturing process more efficient and cost effective.
